Castle Biosciences, Inc.
NASDAQCastle Biosciences reported Q1 2026 results after the bell on May 6 — a revenue beat against a guidance raise — yet the stock slid 3.6% on May 5 ahead of the print, extending what has been a flat-to-weak few weeks for a name down 34% year-to-date. The headline numbers were constructive. Q1 revenue came in at $83.7M, clearing the $79.4M estimate. Adjusted EPS of -$0.49 was in line…
CSTL cost to borrow surges to 1.32%, up 154% in one week, as short interest remains steady at 5.08% of float.
Short interest % of float, cost to borrow, utilization, and put/call ratio for CSTL are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 7 May 2026
Castle Biosciences reported Q1 2026 results after the bell on May 6 — a revenue beat against a guidance raise — yet the stock slid 3.6% on May 5 ahead of the print, extending what has been a flat-to-weak few weeks for…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CSTL — free to start on ORTEX.
Sign up for free →Open CSTL on ORTEX